| Sacituzumab Govitecan studied in …STUDIED_INderived119 of 119show fewer |
|---|
| → studied in | NCT06524544Phase 3 · recruiting A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer · 119 trials list this drug (94 active) | — | — | Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07504588Phase 2 · recruiting Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy · 119 trials list this drug (94 active) | — | — | Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma,Platinum-Sensitive Primary Peritoneal Endometrioid Adenocarcinoma,Platinum-Sensitive Primary Peritoneal High Grade Serous Adenocarcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05327530Phase 2 · active not recruiting A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley) · 119 trials list this drug (94 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05867251Phase 1/Phase 2 · recruiting Study of AVZO-021 in Patients With Advanced Solid Tumors · 119 trials list this drug (94 active) | — | — | Solid Neoplasm,Malignant Fallopian Tube Neoplasm,Ovarian Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06329869Phase 2 · recruiting Sacituzumab Govitecan for Advanced Esophageal Squamous Cell Carcinoma · 119 trials list this drug (94 active) | — | — | Esophageal Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07825753Phase 2 · not yet recruiting Protein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast Cancer · 119 trials list this drug (94 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04579224Phase 3 · active not recruiting Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer · 119 trials list this drug (94 active) | — | — | Urothelial Carcinoma,Bladder Urothelial Carcinoma,Malignant Bladder Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06235216Phase 2 · recruiting Sacituzumab govitEcan in THYroid Cancers · 119 trials list this drug (94 active) | — | — | Thyroid Gland Anaplastic Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05186974Phase 2 · active not recruiting Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) · 119 trials list this drug (94 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06248515Phase 2 · recruiting A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors · 119 trials list this drug (94 active) | — | — | Thymoma,Thymus Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03424005Phase 1/Phase 2 · recruiting A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer · 119 trials list this drug (94 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03606967Phase 2 · recruiting Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer · 119 trials list this drug (94 active) | — | — | Invasive Breast Carcinoma,Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05633654Phase 3 · recruiting Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63) · 119 trials list this drug (94 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06311214Phase 2 · recruiting Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial) · 119 trials list this drug (94 active) | — | — | Malignant Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03547973Phase 2 · active not recruiting Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread · 119 trials list this drug (94 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06161532Phase 2 · recruiting Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C... · 119 trials list this drug (94 active) | — | — | Penile Squamous Cell Carcinoma,Urinary Tract Squamous Cell Carcinoma,Bladder Squamous Cell Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06167317Phase 1 · recruiting Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors · 119 trials list this drug (94 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06263543Phase 2 · recruiting Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC · 119 trials list this drug (94 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06801834Phase 3 · recruiting Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer · 119 trials list this drug (94 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07178730Phase 3 · not yet recruiting NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer · 119 trials list this drug (94 active) | — | — | Malignant Breast Neoplasm,Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03869190Phase 1/Phase 2 · terminated Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC) · 119 trials list this drug (94 active) | — | — | Urothelial Carcinoma,Malignant Bladder Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06081244Phase 3 · recruiting NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III) · 119 trials list this drug (94 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06486441Phase 3 · active not recruiting Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26) · 119 trials list this drug (94 active) | — | — | Malignant Endometrial Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07339059Phase 2 · recruiting Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer · 119 trials list this drug (94 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05838521Phase 2 · recruiting A Study of Sacituzumab Govitecan (IMMU-132) in Patients With Recurrent or Persistent Cervical Cancer · 119 trials list this drug (94 active) | — | — | Malignant Cervical Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04826341Phase 1/Phase 2 · completed A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors · 119 trials list this drug (94 active) | — | — | Solid Neoplasm,Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05552001Phase 3 · active not recruiting Safety and Efficacy Analysis of an Antibody Associated With a Chemotherapy for Patients With a Triple Negative Metastatic Breast Cancer · 119 trials list this drug (94 active) | — | — | Malignant Breast Neoplasm,Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05833867Phase 1 · recruiting Adaptive RADiation Therapy With Concurrent Sacituzumab Govitecan (SG) for Muscle Invasive Bladder Cancer · 119 trials list this drug (94 active) | — | — | Muscle Invasive Bladder Carcinoma,Muscle Invasive Bladder Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04230109Phase 2 · recruiting Sacituzumab Govitecan In TNBC · 119 trials list this drug (94 active) | — | — | Invasive Breast Carcinoma,Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05006794Phase 1 · terminated Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies · 119 trials list this drug (94 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05884320Phase 2 · recruiting Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland Cancers · 119 trials list this drug (94 active) | — | — | Malignant Salivary Gland Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04039230Phase 1/Phase 2 · active not recruiting Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer. · 119 trials list this drug (94 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05101096Phase 1/Phase 2 · active not recruiting Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors · 119 trials list this drug (94 active) | — | — | Solid Neoplasm,Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07011654Phase 1/Phase 2 · recruiting Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC) · 119 trials list this drug (94 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05770531Phase 2 · recruiting Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy · 119 trials list this drug (94 active) | — | — | HER2-Negative Breast Carcinoma,Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04986579Phase 2 · recruiting Scalp Cooling in MBC · 119 trials list this drug (94 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06055465Phase 2 · active not recruiting Neoadjuvant Sacituzumab Govitecan Plus Pembrolizumab in Resectable Non-Small Cell Lung Cancer · 119 trials list this drug (94 active) | — | — | Malignant Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04251416Phase 2 · active not recruiting A Study of Sacituzumab Govitecan (IMMU-132) in Endometrial Carcinoma · 119 trials list this drug (94 active) | — | — | Endometrial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03725761Phase 2 · active not recruiting Sacituzumab Govitecan in Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Second Generation AR-Directed Therapy · 119 trials list this drug (94 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04527991Phase 3 · completed Study of Sacituzumab Govitecan Versus Physician's Choice of Treatment in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread · 119 trials list this drug (94 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04617522Phase 1 · recruiting Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment · 119 trials list this drug (94 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05633667Phase 2 · active not recruiting Study of Novel Treatment Combinations in Patients With Lung Cancer · 119 trials list this drug (94 active) | — | — | Lung Neoplasm,Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06477419Phase 2 · recruiting A Study of Sacituzumab Govitecan in People With Mesothelioma · 119 trials list this drug (94 active) | — | — | Malignant Mesothelioma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07461454Phase 3 · recruiting YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer · 119 trials list this drug (94 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06963905Phase 1/Phase 2 · recruiting Saci Nivo Rela for TNBC · 119 trials list this drug (94 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05675579Phase 2 · active not recruiting A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC) · 119 trials list this drug (94 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06431633Phase 3 · recruiting Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free. · 119 trials list this drug (94 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07492914Phase 2 · recruiting Neoadjuvant Sacituzumab Govitecan Plus Tagitanlimab for Resectable Head and Neck Squamous Cell Carcinoma · 119 trials list this drug (94 active) | — | — | Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07582887recruiting Impact of Genetic Variants on the Toxicity of Antibody-Drug Conjugates in Locally Advanced or Metastatic Breast Cancer: The Role of the UGT1A1 Gene as a Predictive Biomarker of Therapeutic Response · 119 trials list this drug (94 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03337698Phase 1/Phase 2 · terminated A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) · 119 trials list this drug (94 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05089734Phase 3 · active not recruiting Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) · 119 trials list this drug (94 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05601440Phase 2 · recruiting Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer · 119 trials list this drug (94 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04647916Phase 2 · active not recruiting Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases · 119 trials list this drug (94 active) | — | — | Invasive Breast Carcinoma,HER2-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04434040Phase 2 · recruiting Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA) · 119 trials list this drug (94 active) | — | — | Malignant Neoplasm,Malignant Breast Neoplasm,Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05143229Phase 1 · active not recruiting Alpelisib And Sacituzumab Govitecan For Treatment Of Breast Cancer · 119 trials list this drug (94 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07134556Phase 2 · withdrawn Phase II Trial Evaluating the Safety and Efficacy of the Combination of Zimberelimab, Domvanalimab and Sacituzumab Govitecan as 1L Therapy for PD-L1 Positive Advanced TNBC · 119 trials list this drug (94 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06682728Phase 2 · recruiting Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma at High-Risk Recurrence · 119 trials list this drug (94 active) | — | — | Transitional Cell Carcinoma,Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04468061Phase 2 · recruiting Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC · 119 trials list this drug (94 active) | — | — | Malignant Breast Neoplasm,Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03964727Phase 2 · active not recruiting Study of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors · 119 trials list this drug (94 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07328490Phase 1/Phase 2 · withdrawn Bispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate Sacituzumab Govitecan in Previously Treated Extensive-Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancer · 119 trials list this drug (94 active) | — | — | Extrapulmonary Neuroendocrine Carcinoma,Small Cell Neuroendocrine Carcinoma,Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05581589Phase 2 · terminated Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder Cancer · 119 trials list this drug (94 active) | — | — | Malignant Bladder Neoplasm,Muscle Invasive Bladder Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04595565Phase 3 · active not recruiting Sacituzumab Govitecan in Primary HER2-negative Breast Cancer · 119 trials list this drug (94 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03971409Phase 2 · active not recruiting Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer · 119 trials list this drug (94 active) | — | — | Malignant Breast Neoplasm,Breast Carcinoma,Invasive Breast Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07533123Phase 3 · recruiting A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care · 119 trials list this drug (94 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04794699Phase 1 · active not recruiting Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion · 119 trials list this drug (94 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05382299Phase 3 · active not recruiting Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer · 119 trials list this drug (94 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04559230Phase 2 · recruiting Sacituzumab Govitecan in Recurrent Glioblastoma · 119 trials list this drug (94 active) | — | — | Glioblastoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05226117Phase 2 · completed Sacituzumab Govitecan, Preceding Radical Cystectomy, in Treating Patients With Muscle-invasive Bladder Cancer · 119 trials list this drug (94 active) | — | — | Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04143711Phase 1/Phase 2 · completed Study of DF1001 in Patients With Advanced Solid Tumors · 119 trials list this drug (94 active) | — | — | Adult Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06133517Phase 2 · active not recruiting PeRioperative Immunotherapy Combined With Sacituzumab Govitecan in Muscle Invasive blAdder Cancer · 119 trials list this drug (94 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06028932Phase 2 · active not recruiting A Study of Sacituzumab Govitecan (IMMU-132) in Platinum-resistant Ovarian Cancer Patients · 119 trials list this drug (94 active) | — | — | Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06100874Phase 2 · active not recruiting A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN) · 119 trials list this drug (94 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06178588Phase 2 · active not recruiting Sacituzumab Govitecan for the Treatment for Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma · 119 trials list this drug (94 active) | — | — | Intrahepatic Cholangiocarcinoma,Cholangiocarcinoma,Hilar Cholangiocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07063212Phase 2 · recruiting A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC) · 119 trials list this drug (94 active) | — | — | Head and Neck Squamous Cell Carcinoma,Malignant Laryngeal Neoplasm,Malignant Nasal Cavity Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04639986Phase 3 · active not recruiting Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC) · 119 trials list this drug (94 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07393555Phase 2 · not yet recruiting Treatment for Advanced Non-small Cell Lung Cancer With Actionable Genomic Alterations After Targeted Treatment and Chemotherapy (An Expanded Lung-MAP Treatment Trial) · 119 trials list this drug (94 active) | — | — | Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04454437Phase 2 · active not recruiting Study of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior Treatments · 119 trials list this drug (94 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06926920Phase 1/Phase 2 · recruiting A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer · 119 trials list this drug (94 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07367178Phase 2 · not yet recruiting Study of Sacituzumab Govitecan With Atropine to Improve Tolerability in Advanced TNBC and HR+/HER2- Breast Cancer · 119 trials list this drug (94 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm,Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07368543Phase 2 · not yet recruiting Sequencing SG vs. T-DXd in HER2-Low/TROP2-High Metastatic Breast Cancer · 119 trials list this drug (94 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07359404Phase 2 · enrolling by invitation Sacituzumab Govitecan Plus Bevacizumab in Metastatic TNBC · 119 trials list this drug (94 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06865677Phase 2 · terminated Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas · 119 trials list this drug (94 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04448886Phase 2 · active not recruiting Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC · 119 trials list this drug (94 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm,Invasive Breast Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05609968Phase 3 · active not recruiting Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46) · 119 trials list this drug (94 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07299409Phase 2 · not yet recruiting First-Line Sacituzumab Govitecan in Advanced Untreated Triple-Negative Breast Cancer Patients. · 119 trials list this drug (94 active) | — | — | Malignant Breast Neoplasm,Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04863885Phase 1/Phase 2 · active not recruiting Combination of Ipi/Nivo Plus Sacituzumab Govitecan in Metastatic Cisplatin Ineligible Urothelial Carcinoma Patients · 119 trials list this drug (94 active) | — | — | Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06238921Phase 1/Phase 2 · recruiting Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases · 119 trials list this drug (94 active) | — | — | Malignant Breast Neoplasm,Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05520723Phase 2 · completed Preventive stRategy for IMMU132-relatED AEs in TNBC or Luminal Breast Cancer- PRIMED · 119 trials list this drug (94 active) | — | — | Malignant Breast Neoplasm,Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06409390Phase 2 · recruiting Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer · 119 trials list this drug (94 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07251868recruiting Evaluation of Trop-2 ADC in Breast Cancer Patients With Brain Metastases: A Real-World Study · 119 trials list this drug (94 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05119907Phase 2 · active not recruiting Study of Sacituzumab Govitecan in Patients With Solid Tumor · 119 trials list this drug (94 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04724018Phase 1/Phase 2 · recruiting Sacituzumab Govitecan Plus EV in Metastatic UC · 119 trials list this drug (94 active) | — | — | Urothelial Carcinoma,Malignant Bladder Neoplasm,Renal Pelvis and Ureter Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04958785Phase 2 · terminated Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer · 119 trials list this drug (94 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05840211Phase 3 · active not recruiting Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy · 119 trials list this drug (94 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06462092Phase 1/Phase 2 · recruiting Sacituzumab Govitecan and Intrathecal Chemotherapy for Treating Leptomeningeal Metastases From Her2-negative Breast Cancer · 119 trials list this drug (94 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06827613Phase 1/Phase 2 · recruiting A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors · 119 trials list this drug (94 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05382286Phase 3 · active not recruiting Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer · 119 trials list this drug (94 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07040644Phase 2 · not yet recruiting A Study of Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L1 Positive Advanced TNBC · 119 trials list this drug (94 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06923826Phase 2 · recruiting Sacituzumab Govitecan in Metastatic Salivary Gland and Thyroid Cancers (SG-SGTC) · 119 trials list this drug (94 active) | — | — | Malignant Salivary Gland Neoplasm,Malignant Thyroid Gland Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07046455NA · recruiting Trop-2 Targeted PET Probes in Advanced TNBC · 119 trials list this drug (94 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06665178Phase 2 · recruiting Genomic and Transcriptomic Predictors of Sequential SG Sensitivity After T-DXd in ER+/HER2-Low Metastatic Breast Cancer · 119 trials list this drug (94 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05332561Phase 2 · recruiting Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE) · 119 trials list this drug (94 active) | — | — | Early Stage Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05113966Phase 2 · terminated Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer · 119 trials list this drug (94 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05097599Phase 2 · terminated StrataPATH™ (Precision Indications for Approved Therapies) · 119 trials list this drug (94 active) | — | — | Malignant Neoplasm,Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06739395Phase 2 · recruiting Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion · 119 trials list this drug (94 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06102824Phase 2 · recruiting Organoid-based Functional Precision Therapy for Advanced Breast Cancer · 119 trials list this drug (94 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03901339Phase 3 · completed Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer · 119 trials list this drug (94 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03995706early Phase 1 · completed Neuro/Sacituzumab Govitecan/Breast Brain Metastasis/Glioblastoma/Ph 0 · 119 trials list this drug (94 active) | — | — | Glioblastoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06236269Phase 2 · recruiting HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Sacituzumab Govitecan · 119 trials list this drug (94 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06243393Phase 2/Phase 3 · recruiting Sacituzumab Govitecan in Metastatic Colorectal Cancer · 119 trials list this drug (94 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06462079Phase 2 · not yet recruiting Sacituzumab Govitecan Combined With Head Radiotherapy for Her2-negative Breast Cancer Brain Metastases · 119 trials list this drug (94 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04927884Phase 1/Phase 2 · terminated A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior Therapies · 119 trials list this drug (94 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06356519unknown Real-world Effectiveness and Safety Study of Sacituzumab Govitecan in Chinese Metastatic Breast Cancer · 119 trials list this drug (94 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06328387Phase 1/Phase 2 · unknown HCQ+ADC vs ADC in the Treatment of Advanced Breast Cancer · 119 trials list this drug (94 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03992131Phase 1/Phase 2 · terminated A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR) · 119 trials list this drug (94 active) | — | — | Solid Neoplasm,Malignant Ovarian Neoplasm,Urothelial Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02574455Phase 3 · completed Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC) · 119 trials list this drug (94 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05008510Phase 2 · withdrawn P2 Clinical Efficacy & Safety Study of V-111 Monotherapy & Sacituzumab Govitecan-hziy/V-111 Combo Therapy for mTNBC . · 119 trials list this drug (94 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04320693approved for marketing Expanded Access for IMMU-132 · 119 trials list this drug (94 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01631552Phase 1/Phase 2 · completed Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer · 119 trials list this drug (94 active) | — | — | Glioblastoma,Malignant Esophageal Neoplasm,Malignant Pancreatic Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |